X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare SUVEN LIFE with Unichem Lab - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUVEN LIFE vs UNICHEM LAB - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUVEN LIFE UNICHEM LAB SUVEN LIFE/
UNICHEM LAB
 
P/E (TTM) x 19.2 30.2 63.7% View Chart
P/BV x 3.6 3.2 112.2% View Chart
Dividend Yield % 1.0 0.6 175.7%  

Financials

 SUVEN LIFE   UNICHEM LAB
EQUITY SHARE DATA
    SUVEN LIFE
Mar-16
UNICHEM LAB
Mar-16
SUVEN LIFE/
UNICHEM LAB
5-Yr Chart
Click to enlarge
High Rs339334 101.3%   
Low Rs144174 83.0%   
Sales per share (Unadj.) Rs39.2146.9 26.7%  
Earnings per share (Unadj.) Rs7.511.9 62.7%  
Cash flow per share (Unadj.) Rs8.816.2 54.2%  
Dividends per share (Unadj.) Rs2.002.00 100.0%  
Dividend yield (eoy) %0.80.8 105.2%  
Book value per share (Unadj.) Rs49.0105.1 46.6%  
Shares outstanding (eoy) m127.2890.84 140.1%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x6.21.7 355.8%   
Avg P/E ratio x32.421.4 151.5%  
P/CF ratio (eoy) x27.515.7 175.3%  
Price / Book Value ratio x4.92.4 203.9%  
Dividend payout %26.816.8 159.4%   
Avg Mkt Cap Rs m30,73223,073 133.2%   
No. of employees `0001.05.7 16.8%   
Total wages/salary Rs m4162,558 16.3%   
Avg. sales/employee Rs Th5,236.12,352.5 222.6%   
Avg. wages/employee Rs Th436.5450.9 96.8%   
Avg. net profit/employee Rs Th995.5190.4 522.7%   
INCOME DATA
Net Sales Rs m4,99513,346 37.4%  
Other income Rs m194192 100.8%   
Total revenues Rs m5,18913,538 38.3%   
Gross profit Rs m1,2331,639 75.2%  
Depreciation Rs m167390 42.9%   
Interest Rs m5429 188.2%   
Profit before tax Rs m1,2051,412 85.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-4 0.0%   
Extraordinary Inc (Exp) Rs m0-35 0.0%   
Tax Rs m255293 87.1%   
Profit after tax Rs m9501,080 87.9%  
Gross profit margin %24.712.3 200.9%  
Effective tax rate %21.220.7 102.1%   
Net profit margin %19.08.1 234.8%  
BALANCE SHEET DATA
Current assets Rs m4,9865,979 83.4%   
Current liabilities Rs m1,0422,432 42.9%   
Net working cap to sales %79.026.6 297.0%  
Current ratio x4.82.5 194.6%  
Inventory Days Days6163 96.7%  
Debtors Days Days3960 64.8%  
Net fixed assets Rs m3,1266,403 48.8%   
Share capital Rs m127182 70.1%   
"Free" reserves Rs m3,7179,293 40.0%   
Net worth Rs m6,2369,548 65.3%   
Long term debt Rs m432230 187.6%   
Total assets Rs m8,07912,843 62.9%  
Interest coverage x23.250.0 46.4%   
Debt to equity ratio x0.10 287.3%  
Sales to assets ratio x0.61.0 59.5%   
Return on assets %12.48.6 143.9%  
Return on equity %15.211.3 134.6%  
Return on capital %18.914.3 131.7%  
Exports to sales %87.529.2 299.4%   
Imports to sales %12.26.3 192.7%   
Exports (fob) Rs m4,3713,900 112.1%   
Imports (cif) Rs m611847 72.1%   
Fx inflow Rs m4,6664,356 107.1%   
Fx outflow Rs m9421,162 81.1%   
Net fx Rs m3,7243,194 116.6%   
CASH FLOW
From Operations Rs m9221,119 82.4%  
From Investments Rs m-619-853 72.6%  
From Financial Activity Rs m-698-334 209.0%  
Net Cashflow Rs m-396-68 579.4%  

Share Holding

Indian Promoters % 63.4 50.1 126.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.0 15.1 -  
FIIs % 0.0 3.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 36.5 31.7 115.1%  
Shareholders   37,287 20,176 184.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUVEN LIFE With:   DR. REDDYS LAB  IPCA LABS  JUBILANT LIFE SCIENCES  SUN PHARMA  PIRAMAL ENTERPRISES  

Compare SUVEN LIFE With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades in Red; PSU & Energy Stocks Decline(01:30 pm)

Indian share markets continued to trade in red during the noon session weak Asian markets. PSU stocks and energy stocks are witnessing majority of the selling activity.

Related Views on News

Suven Lifesciences: Profits Decline due to Higher tax outgo in the quarter (Quarterly Results Update - Detailed)

Sep 22, 2017

Muted growth in CRAMS segment continues to impact topline.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SUVEN LIFE SHARE PRICE


Feb 22, 2018 01:53 PM

TRACK SUVEN LIFE

  • Track your investment in SUVEN LIFE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SUVEN LIFE - SUN PHARMA COMPARISON

COMPARE SUVEN LIFE WITH

MARKET STATS